Results 11 to 20 of about 14,917 (287)

July 2017 ENCALS statement on edaravone [PDF]

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
Neurologists of the ENCALS centers throughout Europe have discussed the potential of edaravone as a new therapy for amyotrophic lateral sclerosis (ALS, Motor Neuron Disease, MND) at the ENCALS meeting, 18–20 May 2017, in Ljubljana, Slovenia.
Al-Chalabi, A., Andersen, P.M., Chandran, S., Chio, A., Christoph Koch, J., Corcia, P., Couratier, P., Danielsson, O., de Carvalho, M., Desnuelle, C., Grehl, T., Grosskreutz, J., Hardiman, O., Holmøy, T., Ingre, C., Karlsborg, M., Kleveland, G., Koritnik, B., KuzmaKozakiewicz, M., Laaksovirta, H., Ludolph, A., McDermott, C., Meyer, T., Mitre Ropero, B., Mora Pardina, J., Nygren, I., Petri, S., Povedano Panades, M., Salachas, F., Shaw, P., Silani, V., Staaf, G., Svenstrup, K., Talbot, K., Tysnes, O.-B., Van Damme, P., van den Berg, L.H., van der Kooi, A., Weber, M., Weydt, P., Wolf, J.   +40 more
core   +20 more sources

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].

PLoS ONE, 2022
BackgroundEdaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19).
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang, Stephen Apple   +5 more
doaj   +3 more sources

Edaravone Modulates Neuronal GPX4/ACSL4/5-LOX to Promote Recovery After Spinal Cord Injury

Frontiers in Cell and Developmental Biology, 2022
The FDA-approved drug edaravone has a neuroprotective effect on spinal cord injury (SCI) and many other central nervous system diseases. However, its molecular mechanism remains unclear.
Yilin Pang, Xinjie Liu, Xu Wang, Xuelian Shi, Lei Ma, Yan Zhang, Tiangang Zhou, Chenxi Zhao, Xu Zhang, Baoyou Fan, Jian Hao, Wenxiang Li, Xiaoqing Zhao, Rong Zhang, Songlin Zhou, Xiaohong Kong, Shiqing Feng, Shiqing Feng, Xue Yao, Xue Yao   +19 more
doaj   +2 more sources

Antiviral Effect and Mechanism of Edaravone against Grouper Iridovirus Infection

Viruses, 2023
Singapore grouper iridovirus (SGIV) is a virus with high fatality rate in the grouper culture industry. The outbreak of SGIV is often accompanied by a large number of grouper deaths, which has a great impact on the economy.
Jihui Kuang, Mingzhu Liu, Qing Yu, Yuan Cheng, Jing Huang, Shuyu Han, Jingu Shi, Lin Huang, Pengfei Li   +8 more
doaj   +2 more sources

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Antioxidants, 2022
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases ...
Sun Joo Cha, Kiyoung Kim
doaj   +2 more sources

Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage

Frontiers in Pharmacology, 2022
Edaravone dexborneol is a novel neuroprotective drug that comprises edaravone and (+)-borneol in a 4:1 ratio. Phase II and III studies have demonstrated that Chinese patients treated with edaravone dexborneol within 48 h of AIS onset have better ...
Qian Chen, Yichen Cai, Xiaoyu Zhu, Jing Wang, Feng Gao, Mingfeng Yang, Leilei Mao, Zongyong Zhang, Baoliang Sun   +8 more
doaj   +2 more sources

Edaravone: A Possible Treatment for Acute Lung Injury. [PDF]

Int J Gen Med
Despite technological advances in science and medicine, acute lung injury (ALI) is still associated with high mortality rates in the ICU. Therefore, finding novel drugs and treatment approaches is crucial to preventing ALI.
Huang M, Mo Y, Lei H, Chen M.
europepmc   +5 more sources

Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis [PDF]

Journal of Comparative Effectiveness Research
Aim: To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava R IV, Mitsubishi Tanabe Pharma America [MTPA], hereafter ”IV edaravone”) in a real ...
James D Berry, Melissa Hagan, Jeffrey Zhang, Ying Liu, Malgorzata Ciepielewska   +4 more
doaj   +2 more sources

Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke [PDF]

BMC Neurology, 2011
Background Although free radicals have been reported to play a role in the expansion of ischemic brain lesions, the effect of free radical scavengers is still under debate.
Suzuki Akifumi, Yoshioka Shotaroh, Nakase Taizen   +2 more
doaj   +4 more sources

HR-MS Analysis of the Covalent Binding of Edaravone to 5-Formylpyrimidine Bases and a DNA Oligonucleotide Containing a 5-Formylcytidine Residue. [PDF]

Rapid Commun Mass Spectrom
ABSTRACT Rationale Edaravone (EDA) is a radical scavenger and an antioxidant drug approved to treat amyotrophic lateral sclerosis and used as a research tool to explore treatment of neurodegenerative diseases and cancers. It is also a reactive agent, known as PMP (1‐phenyl‐3‐methyl‐5‐pyrazolone), used for the analysis of polysaccharides composition ...
Regnault R, Kouach M, Goossens L, Thuru X, Bailly C, Goossens JF.   +5 more
europepmc   +2 more sources